DK171021B1 - Glycerolderivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdende disse - Google Patents
Glycerolderivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdende disse Download PDFInfo
- Publication number
- DK171021B1 DK171021B1 DK304090A DK304090A DK171021B1 DK 171021 B1 DK171021 B1 DK 171021B1 DK 304090 A DK304090 A DK 304090A DK 304090 A DK304090 A DK 304090A DK 171021 B1 DK171021 B1 DK 171021B1
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- methyl
- methoxy
- octadecylamino
- tlc
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 18
- 150000002314 glycerols Chemical class 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000008569 process Effects 0.000 title claims description 4
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 58
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- -1 N-alkylamine Inorganic materials 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000005131 dialkylammonium group Chemical group 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000005208 trialkylammonium group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000007858 starting material Substances 0.000 description 14
- OHTPZWRWJRNDGC-UHFFFAOYSA-N [1-hydroxy-3-[methyl(octadecyl)amino]propan-2-yl] n-methylcarbamate Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC(=O)NC OHTPZWRWJRNDGC-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 9
- UMVHFZWXXHZDMR-UHFFFAOYSA-N 3-methoxy-2-[methyl(octadecyl)amino]propan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCN(C)C(CO)COC UMVHFZWXXHZDMR-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- UZRODHKANBIDEQ-UHFFFAOYSA-N (2-methoxy-3-phenylmethoxypropyl) methanesulfonate Chemical compound CS(=O)(=O)OCC(OC)COCC1=CC=CC=C1 UZRODHKANBIDEQ-UHFFFAOYSA-N 0.000 description 4
- XWFZEOQPMROJSH-UHFFFAOYSA-N 2-methoxy-3-phenylmethoxypropan-1-ol Chemical compound COC(CO)COCC1=CC=CC=C1 XWFZEOQPMROJSH-UHFFFAOYSA-N 0.000 description 4
- VGRWLSCCYCJYST-UHFFFAOYSA-N 5-methoxy-2-phenyl-1,3-dioxane Chemical compound O1CC(OC)COC1C1=CC=CC=C1 VGRWLSCCYCJYST-UHFFFAOYSA-N 0.000 description 4
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- SIYUYHKHJHZJRV-UHFFFAOYSA-N n-(2-methoxy-3-phenylmethoxypropyl)-n-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(OC)COCC1=CC=CC=C1 SIYUYHKHJHZJRV-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IYNSPGKFJQIGAI-UHFFFAOYSA-N (3-methoxy-2-phenylmethoxypropyl) methanesulfonate Chemical compound CS(=O)(=O)OCC(COC)OCC1=CC=CC=C1 IYNSPGKFJQIGAI-UHFFFAOYSA-N 0.000 description 3
- MAVZHVYMTQPFSW-UHFFFAOYSA-N 1-[methyl(octadecyl)amino]-3-trityloxypropan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(O)CN(C)CCCCCCCCCCCCCCCCCC)C1=CC=CC=C1 MAVZHVYMTQPFSW-UHFFFAOYSA-N 0.000 description 3
- OPGDPALMUNOHNY-UHFFFAOYSA-N 3-methoxy-2-phenylmethoxypropan-1-ol Chemical compound COCC(CO)OCC1=CC=CC=C1 OPGDPALMUNOHNY-UHFFFAOYSA-N 0.000 description 3
- XRCNTWXLLFNXRS-UHFFFAOYSA-N 4-(methoxymethyl)-2-phenyl-1,3-dioxolane Chemical compound O1C(COC)COC1C1=CC=CC=C1 XRCNTWXLLFNXRS-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- SZEGKVHRCLBFKJ-UHFFFAOYSA-N n-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNC SZEGKVHRCLBFKJ-UHFFFAOYSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- DVMSBLKKOUDZGO-UHFFFAOYSA-N 1-(18-benzylsulfonyloctadecylamino)-2-methoxypropan-1-ol Chemical compound C(C1=CC=CC=C1)S(=O)(=O)CCCCCCCCCCCCCCCCCCNC(C(C)OC)O DVMSBLKKOUDZGO-UHFFFAOYSA-N 0.000 description 2
- SBMUNILHNJLMBF-UHFFFAOYSA-N 2-chloro-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound ClP1(=O)OCCO1 SBMUNILHNJLMBF-UHFFFAOYSA-N 0.000 description 2
- CJLGREYPKZVCDD-UHFFFAOYSA-N 2-ethoxy-3-[methyl(octadecyl)amino]propan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OCC CJLGREYPKZVCDD-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- JUEQJOISLBWRCC-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCNCC(CO)OC.C[N+](C)(C)CCOP([O-])(O)=O Chemical compound CCCCCCCCCCCCCCCCCCNCC(CO)OC.C[N+](C)(C)CCOP([O-])(O)=O JUEQJOISLBWRCC-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- ILDGWDSXWRWMCI-UHFFFAOYSA-N [1-[methyl(octadecyl)amino]-3-trityloxypropan-2-yl] n-methylcarbamate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(CN(C)CCCCCCCCCCCCCCCCCC)OC(=O)NC)C1=CC=CC=C1 ILDGWDSXWRWMCI-UHFFFAOYSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- FKEVCKDOZFIRFN-UHFFFAOYSA-N n-(1-methoxy-3-trityloxypropan-2-yl)-n-methyloctadecan-1-amine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(COC)N(C)CCCCCCCCCCCCCCCCCC)C1=CC=CC=C1 FKEVCKDOZFIRFN-UHFFFAOYSA-N 0.000 description 2
- MDOLWCQYUIWYDK-UHFFFAOYSA-N n-(3-methoxy-2-phenylmethoxypropyl)-n-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(COC)OCC1=CC=CC=C1 MDOLWCQYUIWYDK-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- JMMIQBNIFUGPOJ-UHFFFAOYSA-N (2-ethoxy-3-phenylmethoxypropyl) methanesulfonate Chemical compound CS(=O)(=O)OCC(OCC)COCC1=CC=CC=C1 JMMIQBNIFUGPOJ-UHFFFAOYSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- DHILWXDGDAHFPS-UHFFFAOYSA-N 1-methoxy-3-[methyl(octadecyl)amino]propan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)COC DHILWXDGDAHFPS-UHFFFAOYSA-N 0.000 description 1
- CFGZFJURSLUAAR-UHFFFAOYSA-N 18-benzylsulfonyl-N-(2-methoxy-1-phenylmethoxypropyl)octadecan-1-amine Chemical compound C(C1=CC=CC=C1)S(=O)(=O)CCCCCCCCCCCCCCCCCCNC(C(C)OC)OCC1=CC=CC=C1 CFGZFJURSLUAAR-UHFFFAOYSA-N 0.000 description 1
- BRFKGNAQKMAVPT-UHFFFAOYSA-N 18-benzylsulfonyl-n-(3-methoxy-2-phenylmethoxypropyl)octadecan-1-amine Chemical compound C=1C=CC=CC=1COC(COC)CNCCCCCCCCCCCCCCCCCCS(=O)(=O)CC1=CC=CC=C1 BRFKGNAQKMAVPT-UHFFFAOYSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical class C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 1
- AUDDNHGBAJNKEH-UHFFFAOYSA-N 2-Phenyl-1,3-dioxolane-4-methanol Chemical compound O1C(CO)COC1C1=CC=CC=C1 AUDDNHGBAJNKEH-UHFFFAOYSA-N 0.000 description 1
- IVFZIJPESUHPAP-UHFFFAOYSA-N 2-ethoxy-3-phenylmethoxypropan-1-ol Chemical compound CCOC(CO)COCC1=CC=CC=C1 IVFZIJPESUHPAP-UHFFFAOYSA-N 0.000 description 1
- MJYLNDRKTQCKNI-UHFFFAOYSA-N 2-methoxy-3-[methyl(octadecyl)amino]propan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC MJYLNDRKTQCKNI-UHFFFAOYSA-N 0.000 description 1
- GZTAXDWPVKMMJG-UHFFFAOYSA-N 3-[methyl(octadecyl)amino]propane-1,2-diol Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)CO GZTAXDWPVKMMJG-UHFFFAOYSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- ISACIJFHWGFOIU-UHFFFAOYSA-N 5-ethoxy-2-phenyl-1,3-dioxane Chemical compound O1CC(OCC)COC1C1=CC=CC=C1 ISACIJFHWGFOIU-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- JQDXAJFJNIXHTH-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCN(C)C(CO)COC.C[N+](C)(C)CCOP([O-])(O)=O Chemical compound CCCCCCCCCCCCCCCCCCN(C)C(CO)COC.C[N+](C)(C)CCOP([O-])(O)=O JQDXAJFJNIXHTH-UHFFFAOYSA-N 0.000 description 1
- VISQVBGFGGWCQU-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC(NC)=O.C[N+](C)(C)CCOP([O-])(O)=O Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC(NC)=O.C[N+](C)(C)CCOP([O-])(O)=O VISQVBGFGGWCQU-UHFFFAOYSA-N 0.000 description 1
- ZPDULWNNOPNOSK-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC.C[N+](C)(C)CCOP([O-])(O)=O Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OC.C[N+](C)(C)CCOP([O-])(O)=O ZPDULWNNOPNOSK-UHFFFAOYSA-N 0.000 description 1
- ROAWXPSLSIXLOJ-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCN(C)CC(CO)OCC.C[N+](C)(C)CCOP([O-])(O)=O Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(CO)OCC.C[N+](C)(C)CCOP([O-])(O)=O ROAWXPSLSIXLOJ-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- KCDCBSGCJLVZND-UHFFFAOYSA-N n-(2-ethoxy-3-phenylmethoxypropyl)-n-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(OCC)COCC1=CC=CC=C1 KCDCBSGCJLVZND-UHFFFAOYSA-N 0.000 description 1
- IJYCHINYUFOSQG-UHFFFAOYSA-N n-(2-methoxy-3-phenylmethoxypropyl)octadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCC(OC)COCC1=CC=CC=C1 IJYCHINYUFOSQG-UHFFFAOYSA-N 0.000 description 1
- BZPUVWRBDGWLDL-UHFFFAOYSA-N n-(3-methoxy-2-phenylmethoxypropyl)octadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCC(COC)OCC1=CC=CC=C1 BZPUVWRBDGWLDL-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000021039 pomes Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/20—Quaternary compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Hydrogenated Pyridines (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898929074A GB8929074D0 (en) | 1989-12-22 | 1989-12-22 | Glycerol derivatives |
| GB898929075A GB8929075D0 (en) | 1989-12-22 | 1989-12-22 | Glycerol derivatives |
| GB8929075 | 1989-12-22 | ||
| GB8929074 | 1989-12-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK304090D0 DK304090D0 (da) | 1990-12-21 |
| DK304090A DK304090A (da) | 1991-06-23 |
| DK171021B1 true DK171021B1 (da) | 1996-04-22 |
Family
ID=26296423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK304090A DK171021B1 (da) | 1989-12-22 | 1990-12-21 | Glycerolderivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdende disse |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5116992A (it) |
| JP (1) | JP2648730B2 (it) |
| KR (1) | KR950012533B1 (it) |
| AR (1) | AR247875A1 (it) |
| AT (1) | AT398423B (it) |
| AU (1) | AU635991B2 (it) |
| BE (1) | BE1004091A3 (it) |
| CA (1) | CA2032254C (it) |
| CH (1) | CH681225A5 (it) |
| DE (1) | DE4041449A1 (it) |
| DK (1) | DK171021B1 (it) |
| ES (1) | ES2027550A6 (it) |
| FI (1) | FI906203A (it) |
| FR (2) | FR2656308B1 (it) |
| GR (1) | GR1000688B (it) |
| HK (1) | HK117993A (it) |
| IE (1) | IE65821B1 (it) |
| IT (1) | IT1243413B (it) |
| LU (1) | LU87860A1 (it) |
| NL (1) | NL9002742A (it) |
| NO (1) | NO178698C (it) |
| NZ (1) | NZ236483A (it) |
| OA (1) | OA09336A (it) |
| PT (1) | PT96322B (it) |
| SE (1) | SE501393C2 (it) |
| TN (1) | TNSN90153A1 (it) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928580D0 (en) * | 1989-12-19 | 1990-02-21 | Scras | 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives |
| US5206027A (en) * | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
| WO1996006620A2 (en) * | 1994-08-29 | 1996-03-07 | Wake Forest University | Lipid analogs for treating viral infections |
| US7135584B2 (en) * | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US5707978A (en) * | 1994-11-22 | 1998-01-13 | Clarion Pharmaceuticals Inc. | Heteroaryl-substituted deoxy glycero-phosphoethanolamines |
| US5730157A (en) * | 1995-12-07 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Method for treating viral infection |
| US5665714A (en) * | 1995-12-07 | 1997-09-09 | Clarion Pharmaceuticals Inc. | N-substituted glycerophosphoethanolamines |
| US5703062A (en) * | 1995-12-07 | 1997-12-30 | Clarion Pharmaceuticals Inc. | N-het-substituted glycerophosphoethanolamines |
| US5827836A (en) * | 1996-11-15 | 1998-10-27 | Clarion Pharmaceuticals Inc. | Retinoid glycerol phospholipid conjugates |
| US5891881A (en) * | 1997-11-21 | 1999-04-06 | Clarion Pharmaceuticals Inc. | Aminoheterocycle-substituted glycerols |
| US20050187192A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| ES2629682T3 (es) | 2004-03-29 | 2017-08-14 | University Of South Florida | Tratamiento efectivo de tumores y cáncer con fosfato de triciribina |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2820893C2 (de) * | 1978-05-12 | 1986-02-20 | A. Nattermann & Cie GmbH, 5000 Köln | Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen |
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
| DE3323871A1 (de) * | 1983-07-02 | 1985-01-03 | A. Nattermann & Cie GmbH, 5000 Köln | Neue 1-o-alkyl-3-amino-propan-1,2-diol-2-o-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US4863941A (en) * | 1985-06-18 | 1989-09-05 | Hoffmann-La Roche Inc. | Glycerol derivatives |
-
1990
- 1990-12-07 GR GR900100847A patent/GR1000688B/el unknown
- 1990-12-12 NO NO905377A patent/NO178698C/no unknown
- 1990-12-12 SE SE9003973A patent/SE501393C2/sv unknown
- 1990-12-13 NL NL9002742A patent/NL9002742A/nl not_active Application Discontinuation
- 1990-12-14 LU LU87860A patent/LU87860A1/fr unknown
- 1990-12-14 CA CA002032254A patent/CA2032254C/en not_active Expired - Fee Related
- 1990-12-17 CH CH4007/90A patent/CH681225A5/fr not_active IP Right Cessation
- 1990-12-17 NZ NZ236483A patent/NZ236483A/xx unknown
- 1990-12-17 FI FI906203A patent/FI906203A/fi not_active Application Discontinuation
- 1990-12-18 BE BE9001220A patent/BE1004091A3/fr not_active IP Right Cessation
- 1990-12-18 AR AR90318644A patent/AR247875A1/es active
- 1990-12-19 FR FR9015902A patent/FR2656308B1/fr not_active Expired - Fee Related
- 1990-12-19 US US07/630,296 patent/US5116992A/en not_active Expired - Fee Related
- 1990-12-19 IT IT02243990A patent/IT1243413B/it active IP Right Grant
- 1990-12-19 TN TNTNSN90153A patent/TNSN90153A1/fr unknown
- 1990-12-19 FR FR909015903A patent/FR2656221B1/fr not_active Expired - Fee Related
- 1990-12-20 IE IE461890A patent/IE65821B1/en not_active IP Right Cessation
- 1990-12-20 AT AT0260590A patent/AT398423B/de not_active IP Right Cessation
- 1990-12-21 OA OA59931A patent/OA09336A/xx unknown
- 1990-12-21 KR KR1019900021354A patent/KR950012533B1/ko not_active IP Right Cessation
- 1990-12-21 DE DE4041449A patent/DE4041449A1/de not_active Ceased
- 1990-12-21 DK DK304090A patent/DK171021B1/da not_active IP Right Cessation
- 1990-12-21 ES ES9003271A patent/ES2027550A6/es not_active Expired - Fee Related
- 1990-12-21 AU AU68379/90A patent/AU635991B2/en not_active Ceased
- 1990-12-21 JP JP2419284A patent/JP2648730B2/ja not_active Expired - Lifetime
- 1990-12-21 PT PT96322A patent/PT96322B/pt not_active IP Right Cessation
-
1993
- 1993-11-04 HK HK1179/93A patent/HK117993A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK171021B1 (da) | Glycerolderivater, fremgangsmåde til deres fremstilling og terapeutiske præparater indeholdende disse | |
| US3018302A (en) | Novel cyclic phosphoric acid ester amides, and the production thereof | |
| CA2001401A1 (en) | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions | |
| GB2239243A (en) | Glycerol derivatives | |
| CA1261342A (en) | Glycerol derivatives, their production and use | |
| CA2032224C (en) | 3-(n-methyl-n-alkyl)-amino 2-methoxymethylene propan 1-ol derivatives, a preparation process of the same and therapeutical compositions containing them | |
| EP0745068A1 (en) | Heteroaryl-substituted deoxy glycero-phosphoethanolamines | |
| KR100729980B1 (ko) | 항종양제로서비스-(ｎ,ｎ'-비스-(2-할로에틸)아미노)포스포라미데이트 | |
| GB2403949A (en) | Combretastatin derivatives | |
| US4565659A (en) | Substituted aminoalkanol phospholipids | |
| EP0174085A2 (en) | Bisarylamides of N,N'-di-[1-aminoalkyl-2]-alkylene diamines having a cardiovascular activity | |
| JPS6054930B2 (ja) | 抗腫瘍剤 | |
| JPS60197654A (ja) | 制癌剤としての（アルキルスルホニル）メタンスルホン酸エステル |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |